Serologic Response to SHINGRIX Vaccine in Patients With CLL and WM Treated With BTK Inhibitors
NCT03771157
·
clinicaltrials.gov ↗
EARLY_PHASE1
Phase
COMPLETED
Status
33
Enrollment
OTHER
Sponsor class
Conditions
Chronic Lymphocytic Leukemia (CLL)
Waldenstrom Macroglobulinemia (WM)
Interventions
DRUG:
Shingrix vaccine
Sponsor
University of Rochester
Collaborators
[object Object]